Iomai received a new US patent which outlines the methods for inducing an immune reponse to Iomai’s novel skin-patch-based vaccine thereby solidifying the company’s position in transcutaneous immunization (TCI).
The company’s TCI technology is a unique method of vaccine delivery which offers needle-free administration and the ability to deliver types of vaccines that are viable by an intramuscular route. The patent expands the coverage of this technology.
“This patent confirms our position as the first company to design a patch-based system that administers vaccine to the skin, a major competitive advantage,” said Stanley Erck, Iomai's CEO.
“This allows us to continue our efforts to develop the first-ever vaccine for traveler's diarrhea in the United States and a needle-free influenza vaccine patch that would be simpler to administer than injectable vaccines.”
This needle-free technology can be applied to a wide range of vaccines, so that Iomai has submitted to the US Department of Health and Human Services (DHHS) a proposal to receive government funding for further development of its adjuvant skin patch for pandemic influenza.
Read more at In-PharmaTechnologist or at Iomai press release.
Comment Preview